NYSE · ALB
Albemarle Corporation
Basic Materials · Chemicals - Specialty
$91.00▼ 2.43% ($2.27)at close
As of 4:00 PM ET
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 33.7% revenue growth a year for 10 years. Our scenarios assume 5.9–10.2%.
That's 2.9× its past 4-year pace.
Value per share
Base case
$4.94
Price used $91.00 is 18.4× this
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
Revenue each value needs
Revenue today $5.9B. The price needs $108B by 2036. Base case: $12.9B. At its recent pace: $17.5B. Bear to Bull: $10.4B to $15.5B.
Revenue today $5.9B. The price needs $108B by 2036. Base case: $12.9B. At its recent pace: $17.5B. Bear to Bull: $10.4B to $15.5B.
Revenue in 2036
today $5.9B
+$94.7Bmore than the Base case · 8.3×
Value per share · Base case
$4.94
Price $91.00
18.4× this
- 10-yr revenue CAGR
- 8.1%
- Ending operating margin
- 8.9%
- Discount rate
- 9.9%
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 7.04% over the last year. Revenue grew 18.32% over the trailing twelve months. Operating margin moved from -4.49% to 11.92%. Free cash flow grew 787.88% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 11.92%. A decisive move in revenue — currently up 18.32% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Albemarle Corporation stands as a global innovator, producing and distributing a diverse portfolio of engineered specialty chemicals.
Market multiples
Stock splits
Every 1 shares became 2
Profitability & growth
Analyst consensus
21
Buy
19
Hold
5
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 4, 2026
Q3 FY26 · EPS est $2.53 · Revenue est $1.5B
Same quarter, year over year
FY26 YTD n/mEach cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $6.70 vs -$0.07 · all 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- -$0.79
- n/m
- FY24
- -$2.34
- —
n/m: last year’s figure was zero, a loss or too small to compare against
Q2 FY26
Reported Aug 5, 2026 · Latest
HoverTap a cell to inspect
Actual
$3.75
Estimate
$3.20
Year over year
n/m
Vs prior quarter
+27.1%
Institutional Sentiment
Albemarle Corporation · ALB
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.